by | Dec 1, 2021 | Briefings
Background As reported in our earlier article, in July 2021, the Enlarged Board of Appeal issued a Press Communiqué with its decision in case G1/21. As a reminder, the Enlarged Board decided that: During a general emergency impairing the parties’ possibilities...
by | Oct 1, 2021 | Briefings
Background Dr Thaler filed two UK patent applications and subsequently filed Form 7’s stating that the inventor for both applications was the AI system “DABUS”. Dr Thaler also indicated on the Form 7’s that he had acquired the right to be...
by Sean Hutchinson | Oct 1, 2021 | Briefings, US & International
Background In 2008, the State Council of China issued its “Outline of the National Intellectual Property Strategy”, which set a target of increasing the administration and use of IP rights in China by 2020. Last year, the State Council Information Office...
by Eddie Bishop | Oct 1, 2021 | Briefings, US & International
Belcher’s patent related to a high-pH formulation of L-epinephrine (L-adrenaline) and was granted with a claim to a formulation of pH 2.8-3.3. The formulation of L-epinephrine was also the subject of a new drug application before the FDA. Hospira, who were...
by | Oct 1, 2021 | Briefings, US & International
Overview Although there are many similarities between Australian design law and that in the EU, the Australian system (“The Commonwealth of Australia’s Designs Act 2003”) has been somewhat outdated in comparison. For example: No grace period was...
Recent Comments